Morgan Stanley
CRNX icon

Morgan Stanley’s Crinetics Pharmaceuticals CRNX Stock Holding History

Morgan Stanley’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.4M Buy
919,686
+150,860
+20% +$6.74M ﹤0.01% 2494
2025
Q4 		$35.8M Buy
768,826
+86,692
+13% +$3.86M ﹤0.01% 2404
2025
Q3 		$28.4M Sell
682,134
-77,888
-10% -$2.49M ﹤0.01% 2549
2025
Q2 		$21.9M Buy
760,022
+245,338
+48% +$7.58M ﹤0.01% 2707
2025
Q1 		$17.3M Buy
514,684
+9,644
+2% +$360K ﹤0.01% 2846
2024
Q4 		$25.8M Sell
505,040
-160,559
-24% -$8.98M ﹤0.01% 2510
2024
Q3 		$34M Sell
665,599
-173,026
-21% -$8.92M ﹤0.01% 2239
2024
Q2 		$37.6M Buy
838,625
+226,425
+37% +$10.5M ﹤0.01% 2020
2024
Q1 		$28.7M Sell
612,200
-684,302
-53% -$26.8M ﹤0.01% 2298
2023
Q4 		$46.1M Buy
1,296,502
+785,181
+154% +$24.1M ﹤0.01% 2546
2023
Q3 		$15.2M Sell
511,321
-234,838
-31% -$4.84M ﹤0.01% 2737
2023
Q2 		$13.4M Buy
746,159
+93,243
+14% +$1.86M ﹤0.01% 2883
2023
Q1 		$10.5M Buy
652,916
+500,328
+328% +$9.26M ﹤0.01% 3098
2022
Q4 		$2.79M Buy
152,588
+50,556
+50% +$891K ﹤0.01% 4232
2022
Q3 		$2M Sell
102,032
-37,584
-27% -$766K ﹤0.01% 4434
2022
Q2 		$2.6M Buy
139,616
+44,326
+47% +$885K ﹤0.01% 4332
2022
Q1 		$2.09M Buy
95,290
+57,312
+151% +$1.16M ﹤0.01% 4491
2021
Q4 		$1.08M Sell
37,978
-30,976
-45% -$764K ﹤0.01% 5015
2021
Q3 		$1.45M Sell
68,954
-113,043
-62% -$2.36M ﹤0.01% 4808
2021
Q2 		$3.43M Sell
181,997
-18,756
-9% -$330K ﹤0.01% 4163
2021
Q1 		$3.07M Buy
200,753
+15,011
+8% +$233K ﹤0.01% 3904
2020
Q4 		$2.62M Buy
185,742
+145,036
+356% +$2.02M ﹤0.01% 3916
2020
Q3 		$638K Sell
40,706
-173,115
-81% -$2.65M ﹤0.01% 4507
2020
Q2 		$3.75M Buy
213,821
+211,570
+9,399% +$3.61M ﹤0.01% 2968
2020
Q1 		$34K Sell
2,251
-15,156
-87% -$311K ﹤0.01% 5596
2019
Q4 		$437K Sell
17,407
-131
-0.7% -$2.49K ﹤0.01% 4997
2019
Q3 		$264K Buy
17,538
+16,249
+1,261% +$316K ﹤0.01% 4994
2019
Q2 		$32K Sell
1,289
-1,693
-57% -$41.9K ﹤0.01% 5776
2019
Q1 		$67K Sell
2,982
-9,201
-76% -$226K ﹤0.01% 5543
2018
Q4 		$365K Sell
12,183
-153
-1% -$4.31K ﹤0.01% 4993
2018
Q3 		$353K Buy
+12,336
New +$366K ﹤0.01% 5182

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Morgan Stanley's CRNX Position: Q1 2026 in Review

Morgan Stanley increased its Crinetics Pharmaceuticals (CRNX) stake by 20% in Q1 2026, buying an estimated $6.74M and bringing the position to 919,686 shares worth $33.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2494.

Morgan Stanley first reported a position in CRNX in Q3 2018 and has held it in 31 quarters since. The position peaked at $46.1M in Q4 2023. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Morgan Stanley held 919,686 shares of Crinetics Pharmaceuticals worth $33.4M as of Q1 2026.
  • Morgan Stanley bought 150,860 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $6.74M.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #2494 holding.
  • Morgan Stanley first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • Morgan Stanley's Crinetics Pharmaceuticals position peaked at $46.1M in Q4 2023.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.